200 related articles for article (PubMed ID: 21443771)
1. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study.
Dauby N; De Wit S; Delforge M; Necsoi VC; Clumeck N
J Int AIDS Soc; 2011 Mar; 14():16. PubMed ID: 21443771
[TBL] [Abstract][Full Text] [Related]
2. Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development.
Chiu CG; Smith D; Salters KA; Zhang W; Kanters S; Milan D; Montaner JSG; Coldman A; Hogg RS; Wiseman SM
BMC Cancer; 2017 Apr; 17(1):270. PubMed ID: 28410587
[TBL] [Abstract][Full Text] [Related]
3. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
Monforte Ad; Abrams D; Pradier C; Weber R; Reiss P; Bonnet F; Kirk O; Law M; De Wit S; Friis-Møller N; Phillips AN; Sabin CA; Lundgren JD;
AIDS; 2008 Oct; 22(16):2143-53. PubMed ID: 18832878
[TBL] [Abstract][Full Text] [Related]
4. Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies.
Spagnuolo V; Galli L; Salpietro S; Gianotti N; Guffanti M; Cossarini F; Bigoloni A; Cinque P; Bossolasco S; Travi G; Fumagalli L; Lazzarin A; Castagna A
Int J Cancer; 2012 Jun; 130(12):2990-6. PubMed ID: 21796633
[TBL] [Abstract][Full Text] [Related]
5. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
Powles T; Robinson D; Stebbing J; Shamash J; Nelson M; Gazzard B; Mandelia S; Møller H; Bower M
J Clin Oncol; 2009 Feb; 27(6):884-90. PubMed ID: 19114688
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
7. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.
Hleyhel M; Hleyhel M; Bouvier AM; Belot A; Tattevin P; Pacanowski J; Genet P; De Castro N; Berger JL; Dupont C; Lavolé A; Pradier C; Salmon D; Simon A; Martinez V; Spano JP; Costagliola D; Grabar S;
AIDS; 2014 Sep; 28(14):2109-18. PubMed ID: 25265077
[TBL] [Abstract][Full Text] [Related]
8. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals.
Long JL; Engels EA; Moore RD; Gebo KA
AIDS; 2008 Feb; 22(4):489-96. PubMed ID: 18301061
[TBL] [Abstract][Full Text] [Related]
9. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study.
Hernández-Ramírez RU; Shiels MS; Dubrow R; Engels EA
Lancet HIV; 2017 Nov; 4(11):e495-e504. PubMed ID: 28803888
[TBL] [Abstract][Full Text] [Related]
10. Malignancies in HIV: pre- and post-highly active antiretroviral therapy.
Nutankalva L; Wutoh AK; McNeil J; Frederick WR; Reddy RB; Daftary M; Gentles A; Addae-Afoakwa K
J Natl Med Assoc; 2008 Jul; 100(7):817-20. PubMed ID: 18672558
[TBL] [Abstract][Full Text] [Related]
11. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression.
Bedimo RJ; McGinnis KA; Dunlap M; Rodriguez-Barradas MC; Justice AC
J Acquir Immune Defic Syndr; 2009 Oct; 52(2):203-8. PubMed ID: 19617846
[TBL] [Abstract][Full Text] [Related]
12. Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy.
Galli L; Spagnuolo V; Poli A; Salpietro S; Gianotti N; Cossarini F; Carbone A; Nozza S; Bossolasco S; Bigoloni A; Lazzarin A; Castagna A
AIDS; 2014 Oct; 28(16):2407-15. PubMed ID: 25160933
[TBL] [Abstract][Full Text] [Related]
13. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
[TBL] [Abstract][Full Text] [Related]
14. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999.
Bonnet F; Morlat P; Chêne G; Mercié P; Neau D; Chossat I; Decoin M; Djossou F; Beylot J; Dabis F;
HIV Med; 2002 Jul; 3(3):195-9. PubMed ID: 12139658
[TBL] [Abstract][Full Text] [Related]
15. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
Herida M; Mary-Krause M; Kaphan R; Cadranel J; Poizot-Martin I; Rabaud C; Plaisance N; Tissot-Dupont H; Boue F; Lang JM; Costagliola D
J Clin Oncol; 2003 Sep; 21(18):3447-53. PubMed ID: 12972519
[TBL] [Abstract][Full Text] [Related]
16. Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era.
Nguyen ML; Farrell KJ; Gunthel CJ
Curr Infect Dis Rep; 2010 Jan; 12(1):46-55. PubMed ID: 21308498
[TBL] [Abstract][Full Text] [Related]
17. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study.
Hessol NA; Whittemore H; Vittinghoff E; Hsu LC; Ma D; Scheer S; Schwarcz SK
Lancet HIV; 2018 Nov; 5(11):e647-e655. PubMed ID: 30245004
[TBL] [Abstract][Full Text] [Related]
18. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.
Worm SW; Bower M; Reiss P; Bonnet F; Law M; Fätkenheuer G; d'Arminio Monforte A; Abrams DI; Grulich A; Fontas E; Kirk O; Furrer H; De Wit S; Phillips A; Lundgren JD; Sabin CA;
BMC Infect Dis; 2013 Oct; 13():471. PubMed ID: 24106926
[TBL] [Abstract][Full Text] [Related]
19. Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART.
Franzetti M; Adorni F; Parravicini C; Vergani B; Antinori S; Milazzo L; Galli M; Ridolfo AL
J Acquir Immune Defic Syndr; 2013 Apr; 62(4):414-20. PubMed ID: 23274934
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer in HIV positive patients: the GICAT experience.
Bearz A; Vaccher E; Martellotta F; Spina M; Talamini R; Lleshi A; Cacopardo B; Nunnari G; Berretta M; Tirelli U;
Eur Rev Med Pharmacol Sci; 2014; 18(4):500-8. PubMed ID: 24610616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
